Lisbon, Portugal, 2017-11-14 - NBE-Therapeutics presented update on R&D activities at 2017-PEGS conference
Roger R. Beerli, CSO of NBE-Therapeutics, will present an update on the company's ADC development activities
Roger R. Beerli has been invited for a presentation in the "Oncology" Stream at the international Protein and Antibody Engineering Summit (PEGS) Europe 2017. The conference is hosted by Cambridge Healthtech Institute (CHI) and is a premier event in the therapeutic antibody and protein drug discovery industry (see: http://www.pegsummiteurope.com/). Roger's presentation was entitled "Anthracycline-based antibody drug conjugates with potent immune-stimulatory functions" and took place on November 14, at 2:45 pm.
Recent news feed
RSS feed from: